June 04, 2025

Stroke Risk in Down Syndrome: Underestimated?

A large population study found that individuals with Down syndrome face a significantly higher risk of stroke, particularly at younger ages, while their risk of heart attack is generally similar to the general population but elevated before age 40.

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

May 28, 2025

Sleep, Time, Exercise Shift Heart Biomarkers, Study Finds 

Short sleep, late blood draws, and intense workouts significantly change common cardiovascular biomarkers, suggesting key variables often go unaccounted for in heart risk assessments.

Conexiant

May 23, 2025

BP Pills: Does Timing Matter? 

A large Canadian study of 3,357 patients found that taking blood pressure medication at bedtime did not reduce deaths or heart events compared to morning dosing.

Conexiant

May 23, 2025

BP Pills: Does Timing Matter? 

A large Canadian study of 3,357 patients found that taking blood pressure medication at bedtime did not reduce deaths or heart events compared to morning dosing.

Conexiant

May 20, 2025

Clinical Trials Missing in Half of AI Tools

Researchers analyzed FDA-approved AI-enabled medical devices and reported that clinical performance and subgroup data were frequently missing.

Conexiant

May 16, 2025

Delandistrogene Moxeparvovec: Efficacy Evidence Questioned

The AAN Guidelines Subcommittee review finds delandistrogene moxeparvovec for DMD failed to meet primary functional outcomes despite FDA approval.

Conexiant

May 15, 2025

Men With Broken Heart Syndrome Have Twice the Mortality Risk: Study

A large U.S. study of nearly 200,000 Takotsubo cardiomyopathy cases found persistently high mortality—especially among men—despite rising incidence and increased recognition from 2016 to 2020.

Conexiant

May 15, 2025

Chikungunya Vaccine Linked to Adverse Events

The FDA and CDC have paused use of the Ixchiq chikungunya vaccine in adults aged 60 and older due to reports of serious postmarketing adverse events.

Conexiant